Help "Statin-Intolerant" Patients Stick With a Statin
The new PCSK9 inhibitor, Repatha (rih-PATH-ah, evolocumab), will raise questions about how to help patients stick with a statin.
Evolocumab is similar to alirocumab (Praluent).
Both PCSK9 inhibitors are injectable biologics...may lower LDL about 60%...cost about $14,000/yr...and lack long-term outcome and safety data.
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote